It is expected that enzalutamide will enhance the CYP3A4 mediated metabolism and decrease the plasmalavels of oxycodone.
ID
Bron
Verkorte titel
Aandoening
Prostate cancer
Pain
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Difference in pharmacokinetics of oxycodone in the presence and absence of enzalutamide, expressed in maximum serum concentration (Cmax) of oxycodone.
Achtergrond van het onderzoek
Rationale: Oxycodone is an opioid receptor agonist that is metabolized mainly in the liver by CYP3A4 and 2D6 enzymes. Enzalutamide is one of the next-generation endocrine agents used in patients with (nonmetastatic and metastatic) CRPC. Because enzalutamide is a strong inducer of CYP3A4, it is expected that enzalutamide will reduce the analgesic effects of oxycodone, which is also metabolised along this pathway. This could have an important impact on patients’ pain-related quality of life and on the effective and safe use of oxycodone and enzalutamide.
Objective: To investigate the effect of enzalutamide on the pharmacokinetics (PK) of oxycodone following a single 15 mg dose of normal-release oxycodone in men with prostate cancer.
Study design: A prospective, open-label, two arm parallel study.
Study population: 24 males aged ≥ 18 years with prostate cancer treated with enzalutamide (arm 1) or not treated with enzalutamide (arm 2).
Intervention: Subjects will receive a single oral dose of normal-release oxycodone 15 mg.
Main study parameters/endpoints: Difference in pharmacokinetics of oxycodone in the presence and absence of enzalutamide, expressed in Cmax.
Doel van het onderzoek
It is expected that enzalutamide will enhance the CYP3A4 mediated metabolism and decrease the plasmalavels of oxycodone.
Onderzoeksopzet
Six time points (t=1, 1.5, 2, 4, 6, 8h) after oxycodone intake.
Onderzoeksproduct en/of interventie
Oxycodone normal-release 15 mg single oral dose in the presence (experimental) and absence (control) of enzalutamide
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Males aged ≥ 18 years;
Diagnosed prostate cancer;
Treated with enzalutamide 160 mg once daily for 40 days (arm 1)
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
known metastases in the liver that would affect drug metabolism;
Child-Pugh classification B or C that would affect drug metabolism;
known moderate-severe renal dysfunction (GFR <60 ml/min/1.73m2) that would affect drug metabolism;
gastrointestinal disorders that would potentially alter absorption;
previous gastric bypass or gastric band surgery;
known allergy, hypersensitivity or intolerance to normal-release oxycodone;
a history of drug abuse or treatment for abuse;
dose-reduction or ≥5 successive days of treatment interruption of enzalutamide within 40 days prior to the study day (arm 1);
treatment with enzalutamide within 40 days prior to the study day (arm 2);
use of oxycodone normal-release within 24 hour prior to oxycodone intake or use of oxycodone extended-release within 2 days prior to oxycodone intake;
use of other medication that would affect oxycodone metabolism, see section 5.2 and appendix B;
use of other medication that would affect enzalutamide metabolism, see section 5.2 and appendix B (arm 1).
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL9077 |
| CCMO | NL.75669.075.20 |